Naslov
Pharmacogenetics in the treatment of cardiovascular diseases - is it cost-effective?

Autori
Božina, Nada ; Ganoci, Lana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
ESHG Pharmacogenetics Course, Portorož, Slovenija, 22-24.09.2022. Book of Abstracts, 2022 / - , 2022, 18-18

Skup
ESHG Pharmacogenetics Course

Mjesto i datum
Portorož, Slovenija, 22.09.2022. - 24.09.2022

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
cardiovascular drugs ; cost-effectiveness ; pharmacogenomics

Sažetak
Pharmacogenomics testing is applied in personalizing drug treatment of various diseases, including cardiovascular disease (CVD), to individualize the therapy with the aim of achieving maximum efficacy while reducing the adverse drug reactions (ADRs) that attributes to a high economic burden, high mortality and morbidity, and higher hospitalization costs globally. Pharmacogenomics-guided therapy is considered cost-effective if it is superior compared to the standard therapy. Health outcomes can be measured according to life years gained, lives saved and avoidance of incidences and hospitalizations. To be cost-effective, pharmacogenomics-guided therapy must be cost saving and give higher quality-adjusted life per year (QALY) than standard therapy. However, pharmacogenomics-guided therapy can also be considered cost-effective if the quality of life that results from the guided treatment gives significantly better quality of life although the cost is more expensive than that of standard care. Genotyping cost and frequency of risk alleles in the populations influence the cost-effectiveness outcome. Most studies used a single gene, rather than a gene panel for pharmacogenomics testing. The majority of studies on the cost- effectiveness of CV drugs focused on warfarin and clopidogrel, and only a few investigated statins and antihypertensive drugs. Data on the costeffectiveness of pharmacogenomics-guided treatment in CVD reveals that most studies performed were cost-effective. However, some studies observed questionable the costeffectiveness of PGx vs standard treatment, while some studies were inconclusive. The data were specifically supportive of pharmacogenomics- guided (CYP2C19) clopidogrel treatment in patients with Acute Coronary Syndrome (ACS) and Atrial Fibrillation. Besides, data showed that the cost-effectiveness of multigene testing (CYP2C19, SLCO1B1, CYP2C9, VKORC1) compared with single-gene testing (CYP2C19) and standard of care (no genotyping) in ACS patients undergoing PCI has a higher probability of being cost-effective. Further studies are warranted to examine the clinical and economic validity of pharmacogenomics testing for CVD.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija, Ekonomija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA